David Fajgenbaum, MD, Research, Philadelphia, PA

DavidCharlesFajgenbaumMDMBA, MSc

Research Philadelphia, PA

Asst Prof of Medicine, Translational Medicine/Human Genetics, UPenn; Executive Director, Castleman Disease Collaborative Network

Dr. Fajgenbaum is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fajgenbaum's full profile

Already have an account?

Education & Training

  • Wharton School - University of PennsylvaniaMBA, Health Care Management, 2013 - 2015
  • Perelman School of Medicine at the University of PennsylvaniaClass of 2013
  • University of OxfordM.S., Public Health, 2008
  • Georgetown UniversityBS, Human Sciences, 2003 - 2007

Awards, Honors, & Recognition

  • RARE Champion of Hope - Science Gloabl Genes, 2015
  • 30 under 30 in Healthcare Forbes, 2015
  • Young Investigators Draft Awardee Uplifting Athletes, 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Cytokine Storm  
    David Fajgenbaum, MD, The New England Journal of Medicine
  • Predictors of response to anti-IL6 monoclonal antibody therapy(siltuximab) in idiopathic multicentric Castleman disease:secondary analyses of phase II clinical trial data  
    Deanna E. Morra, Sheila K. Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C. Fajgenbaum, British Journal of Haematology, 1/1/2018
  • The full spectrum of Castleman Disease: 273 patients studied over 20 years  
    Eric Oksenhendler, David Boutboul, David C. Fajgenbaum, Adrien Mirouse, Claire Fieschi, Marion Malphettes, Laetitia Vercellino, V�ronique Meignin, Laurence G�rard, Lio..., British Journal of Hematology, 1/1/2018
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
    David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
    David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients
    Anna Wiing, Wenzhao Meng, Gerald Wertheim, Dale Frank, Michele Paessler, Megan S. Lim, Eline T. Luning Prak, David C Fajgenbaum, Vinodh Pillai, Blood (ASH Annual Meeting Abstracts), 1/1/2018
  • Join now to see all

Lectures

  • Frontiers in Medicine: Personalized Medicine 
    1/1/2019
  • Overtime: Battling a deadly disease as a physician, researcher, patient, and entrepreneur 
    1/1/2019
  • MOD1 Genetics Case Presentations 
    1/1/2019
  • Join now to see all

Other

  • Unicentric Castleman disease 
    David C. Fajgenbaum, UpToDate
    1/1/2018
  • HHV-8-associated multicentric Castleman disease 
    David C. Fajgenbaum, UpToDate
    1/1/2018
  • HHV-8-negative/idiopathic multicentric Castleman disease 
    David C. Fajgenbaum, UpToDate
    1/1/2018
  • Join now to see all

Authored Content

  • I Was Read My Last Rites as a Third-Year Medical StudentNovember 2019
  • I Was Read My Last Rites as a Third-Year Medical StudentNovember 2019
  • UpToDate - idiopathic multicentric Castleman disease10/17/2018

Press Mentions

  • Penn Researchers Discover Key Mechanism of Cytokine Storm in Castleman Disease
    Penn Researchers Discover Key Mechanism of Cytokine Storm in Castleman DiseaseMay 7th, 2020
  • How Dr. David Fajgenbaum Cured His Own Deadly Disease | Frank Buckley Interviews
    How Dr. David Fajgenbaum Cured His Own Deadly Disease | Frank Buckley InterviewsOctober 2nd, 2019
  • This Med Student Was Given Last Rites Before Finding a Treatment That Saved His Life. His Method Could Help Millions
    This Med Student Was Given Last Rites Before Finding a Treatment That Saved His Life. His Method Could Help MillionsSeptember 15th, 2019
  • Join now to see all

Grant Support

  • mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetNational Institutes of Health - NHLBI2018–2023

Professional Memberships